Overview

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The symptoms associated with COPD include overproduction of mucus and inflammation in the lungs. Overproduction of mucus results in impaired lung function and it encourages bacterial growth and associated COPD exacerbations. Therefore, a treatment that inhibits mucus overproduction or blocks inflammation could benefit COPD patients. The drug under evaluation in this study, BIO-11006 Inhalation Solution, is a new drug that may inhibit overproduction of mucus and may have important anti-inflammatory properties.
Phase:
Phase 2
Details
Lead Sponsor:
BioMarck Pharmaceuticals, Ltd.
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Pharmaceutical Solutions